Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q4fy26: Revenue Surges 18.9%, PAT Up 446%
Dishman Carbogen Amcis Limited (DCAL) reports a 18.9% revenue increase in Q4 FY26, driven by growth in CDMO and Marketable Molecules segments.
Dishman Carbogen Amcis Limited (DCAL) showcased robust financial performance for the quarter and full year ended March 31, 2026. The company reported a net revenue of ₹8,514 million in Q4 FY26, marking an 18.9% increase compared to ₹7,163 million in Q4 FY25. This growth was primarily driven by higher revenue from the CDMO and Marketable Molecules segments. The company’s EBITDA margin stood at 19.1% in Q4 FY26, down from 21.3% in the same quarter of the previous year, due to a decrease in CDMO segment margins.
Quarterly Highlights
In Q4 FY26, DCAL’s CDMO revenue surged by 21.3% year-on-year to ₹6,908.7 million, while Marketable Molecules revenue grew by 9.3% to ₹1,605.3 million. For the full year FY26, the company’s total revenue increased by 8.1% to ₹29,319 million compared to ₹27,115 million in FY25. The EBITDA margin for FY26 was 19.3%, up from 17.3% in FY25.
Full Year Highlights
The full year FY26 results reflected a strong performance with a 3.3% PAT margin, significantly higher than the 0.1% margin in FY25. The company’s focus on improving capacity utilization and targeting small and mid-sized global biotech companies contributed to its successful in-organic growth. With a strong pipeline of 10 molecules in late phase III development, DCAL continues to expand its operations across various geographies.
As we look ahead, DCAL remains committed to its culture of innovation and sustainability, aiming to deliver continued growth and value to its stakeholders.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 1.9x the volume of sellers. Moreover, they dominated on 19 of recent sessions versus 11 for sellers — a healthy accumulation pattern. Price climbs recently despite 8.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.
BIOCON
Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU
Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.
Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.
First Biosimilar Under New Clinical Approach
Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”
Broadening Treatment Options
The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.
As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.
Key Financial Highlights
The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.
Segment Performance
The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.
However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.
As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.
BIOCON
Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection
Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.
Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.
Expanding Access to Affordable Biologics
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
Strengthening Oncology Portfolio
Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
-
Consumer Cyclical2 days agoUflex Limited (NSE: Uflex) Q2 FY27: Strong Performance Amidst Geopolitical Headwinds
-
Consumer Cyclical2 days agoUflex Limited (NSE: Uflex) Q2 FY27: Revenue Up 26.1%, PAT Surges 682.8%
-
Computer Hardware3 days agoTvs Electronics Limited (tvselect) Q2/h1-fy27 Earnings Presentation: Revenue Rebounds, Margins Under Pressure
-
CAPILLARY3 days agoCapillary Technologies India Limited (capillary) Announces Hero Cycles Selects Capillary to Power Loyalty Across its 3,000+ Dealer Network
-
Biotechnology2 days agoDishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
-
Energy2 days agoUnited Drilling Tools Limited UNIDT Q2 FY27: Maintains Profitability Amidst Market Challenges
-
GUJTHEM2 days agoGujarat Themis Biosyn Limited Announces Strategic Acquisition of Microbiopharm Japan
-
BIOCON3 days agoBiocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection